Quaternary glucocorticoid receptor structure highlights allosteric interdomain communication.


Journal

Nature structural & molecular biology
ISSN: 1545-9985
Titre abrégé: Nat Struct Mol Biol
Pays: United States
ID NLM: 101186374

Informations de publication

Date de publication:
03 2023
Historique:
received: 05 04 2022
accepted: 15 12 2022
pubmed: 8 2 2023
medline: 22 3 2023
entrez: 7 2 2023
Statut: ppublish

Résumé

The glucocorticoid receptor (GR) is a ligand-activated transcription factor that binds DNA and assembles co-regulator complexes to regulate gene transcription. GR agonists are widely prescribed to people with inflammatory and autoimmune diseases. Here we present high-resolution, multidomain structures of GR in complex with ligand, DNA and co-regulator peptide. The structures reveal how the receptor forms an asymmetric dimer on the DNA and provide a detailed view of the domain interactions within and across the two monomers. Hydrogen-deuterium exchange and DNA-binding experiments demonstrate that ligand-dependent structural changes are communicated across the different domains in the full-length receptor. This study demonstrates how GR forms a distinct architecture on DNA and how signal transmission can be modulated by the ligand pharmacophore, provides a platform to build a new level of understanding of how receptor modifications can drive disease progression and offers key insight for future drug design.

Identifiants

pubmed: 36747092
doi: 10.1038/s41594-022-00914-4
pii: 10.1038/s41594-022-00914-4
doi:

Substances chimiques

Receptors, Glucocorticoid 0
Ligands 0
Transcription Factors 0
DNA 9007-49-2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

286-295

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer Nature America, Inc.

Références

Eick, G. N. & Thornton, J. W. Evolution of steroid receptors from an estrogen-sensitive ancestral receptor. Mol. Cell. Endocrinol. 334, 31–38 (2011).
pubmed: 20837101 doi: 10.1016/j.mce.2010.09.003
Weikum, E. R., Knuesel, M. T., Ortlund, E. A. & Yamamoto, K. R. Glucocorticoid receptor control of transcription: precision and plasticity via allostery. Nat. Rev. Mol. Cell Biol. 18, 159 (2017).
pubmed: 28053348 pmcid: 6257982 doi: 10.1038/nrm.2016.152
Köhler, C. et al. Dynamic allosteric communication pathway directing differential activation of the glucocorticoid receptor. Sci. Adv. 6, eabb5277 (2020).
pubmed: 32832645 pmcid: 7439413 doi: 10.1126/sciadv.abb5277
Watson, L. C. et al. The glucocorticoid receptor dimer interface allosterically transmits sequence-specific DNA signals. Nat. Struct. Mol. Biol. 20, 876 (2013).
pubmed: 23728292 pmcid: 3702670 doi: 10.1038/nsmb.2595
Zhang, J. et al. DNA binding alters coactivator interaction surfaces of the intact VDR–RXR complex. Nat. Struct. Mol. Biol. 18, 556–563 (2011).
pubmed: 21478866 pmcid: 3087838 doi: 10.1038/nsmb.2046
Meijsing, S. H. et al. DNA binding site sequence directs glucocorticoid receptor structure and activity. Science 324, 407–410 (2009).
pubmed: 19372434 pmcid: 2777810 doi: 10.1126/science.1164265
Schiller, B. J., Chodankar, R., Watson, L. C., Stallcup, M. R. & Yamamoto, K. R. Glucocorticoid receptor binds half sites as a monomer and regulates specific target genes. Genome Biol. 15, 418 (2014).
pubmed: 25085117 pmcid: 4149261 doi: 10.1186/s13059-014-0418-y
Hudson, W. H., Youn, C. & Ortlund, E. A. The structural basis of direct glucocorticoid-mediated transrepression. Nat. Struct. Mol. Biol. 20, 53 (2012).
pubmed: 23222642 pmcid: 3539207 doi: 10.1038/nsmb.2456
Presman, D. M. et al. DNA binding triggers tetramerization of the glucocorticoid receptor in live cells. Proc. Natl Acad. Sci. USA 113, 8236–8241 (2016).
pubmed: 27382178 pmcid: 4961135 doi: 10.1073/pnas.1606774113
Presman, D. M. et al. Live cell imaging unveils multiple domain requirements for in vivo dimerization of the glucocorticoid receptor. PLoS Biol. 12, e1001813 (2014).
pubmed: 24642507 pmcid: 3958349 doi: 10.1371/journal.pbio.1001813
Johnson, T. A., Paakinaho, V., Kim, S., Hager, G. L. & Presman, D. M. Genome-wide binding potential and regulatory activity of the glucocorticoid receptor’s monomeric and dimeric forms. Nat. Commun. 12, 1987 (2021).
pubmed: 33790284 pmcid: 8012360 doi: 10.1038/s41467-021-22234-9
Chandra, V. et al. Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA. Nature 456, 350 (2008).
pubmed: 19043829 pmcid: 2743566 doi: 10.1038/nature07413
Chandra, V. et al. Multidomain integration in the structure of the HNF-4α nuclear receptor complex. Nature 495, 394 (2013).
pubmed: 23485969 pmcid: 3606643 doi: 10.1038/nature11966
Chandra, V. et al. The quaternary architecture of RARβ–RXRα heterodimer facilitates domain–domain signal transmission. Nat. Commun. 8, 868 (2017).
pubmed: 29021580 pmcid: 5636793 doi: 10.1038/s41467-017-00981-y
Lou, X. et al. Structure of the retinoid X receptor α–liver X receptor β (RXRα–LXRβ) heterodimer on DNA. Nat. Struct. Mol. Biol. 21, 277–281 (2014).
pubmed: 24561505 doi: 10.1038/nsmb.2778
Veleiro, A. S., Alvarez, L. D., Eduardo, S. L. & Burton, G. Structure of the glucocorticoid receptor, a flexible protein that can adapt to different ligands. ChemMedChem 5, 649–659 (2010).
pubmed: 20333619 doi: 10.1002/cmdc.201000014
Hemmerling, M. et al. Selective nonsteroidal glucocorticoid receptor modulators for the inhaled treatment of pulmonary diseases. J. Med. Chem. 60, 8591–8605 (2017).
pubmed: 28937774 doi: 10.1021/acs.jmedchem.7b01215
Biggadike, K. et al. X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor−ligand binding domain. J. Med. Chem. 51, 3349–3352 (2008).
pubmed: 18522385 doi: 10.1021/jm800279t
Brown, M. N. et al. Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial. Respiratory Res. 20, 37 (2019).
doi: 10.1186/s12931-019-1000-7
Shefrin, A. E. & Goldman, R. D. Use of dexamethasone and prednisone in acute asthma exacerbations in pediatric patients. Can. Fam. Physician 55, 704–706 (2009).
pubmed: 19602654 pmcid: 2718595
Syed, Y. Y. Fluticasone furoate/vilanterol: a review of its use in patients with asthma. Drugs 75, 407–418 (2015).
pubmed: 25648266 doi: 10.1007/s40265-015-0354-5
Grasso, E. M., Majumdar, A., Wrabl, J. O., Frueh, D. P. & Hilser, V. J. Conserved allosteric ensembles in disordered proteins using TROSY/anti-TROSY R2-filtered spectroscopy. Biophys. J. 120, 2498–2510 (2021).
pubmed: 33901472 pmcid: 8390865 doi: 10.1016/j.bpj.2021.04.017
Shiau, A. K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927–937 (1998).
pubmed: 9875847 doi: 10.1016/S0092-8674(00)81717-1
Bledsoe, R. K. et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 110, 93–105 (2002).
pubmed: 12151000 doi: 10.1016/S0092-8674(02)00817-6
Bianchetti, L. et al. Alternative dimerization interfaces in the glucocorticoid receptor-α ligand binding domain. Biochim. Biophys. Acta 1862, 1810–1825 (2018).
doi: 10.1016/j.bbagen.2018.04.022
Paakinaho, V., Johnson, T. A., Presman, D. M. & Hager, G. L. Glucocorticoid receptor quaternary structure drives chromatin occupancy and transcriptional outcome. Genome Res. 29, 1223–1234 (2019).
Presman, D. M. & Hager, G. L. More than meets the dimer: what is the quaternary structure of the glucocorticoid receptor? Transcription 8, 32–39 (2017).
pubmed: 27764575 doi: 10.1080/21541264.2016.1249045
Kim, D. N., Jacobs, T. M. & Kuhlman, B. Boosting protein stability with the computational design of β-sheet surfaces. Protein Sci. 25, 702–710 (2016).
pubmed: 26701383 pmcid: 4815415 doi: 10.1002/pro.2869
Timmermans, S. et al. Point mutation I634A in the glucocorticoid receptor causes embryonic lethality by reduced ligand binding. J. Biol. Chem. 298, 101574 (2022).
pubmed: 35007536 pmcid: 8808175 doi: 10.1016/j.jbc.2022.101574
Robblee, J. P., Miura, M. T. & Bain, D. L. Glucocorticoid receptor–promoter interactions: energetic dissection suggests a framework for the specificity of steroid receptor-mediated gene regulation. Biochemistry 51, 4463–4472 (2012).
pubmed: 22587663 doi: 10.1021/bi3003956
Hochberg, G. K. A. et al. A hydrophobic ratchet entrenches molecular complexes. Nature 588, 503–508 (2020).
pubmed: 33299178 pmcid: 8168016 doi: 10.1038/s41586-020-3021-2
Tamrazi, A., Carlson, K. E., Daniels, J. R., Hurth, K. M. & Katzenellenbogen, J. A. Estrogen receptor dimerization: ligand binding regulates dimer affinity and dimer dissociation rate. Mol. Endocrinol. 16, 2706–2719 (2002).
pubmed: 12456792 doi: 10.1210/me.2002-0250
Maletta, M. et al. The palindromic DNA-bound USP/EcR nuclear receptor adopts an asymmetric organization with allosteric domain positioning. Nat. Commun. 5, 4139 (2014).
pubmed: 24942373 doi: 10.1038/ncomms5139
Orlov, I., Rochel, N., Moras, D. & Klaholz, B. P. Structure of the full human RXR/VDR nuclear receptor heterodimer complex with its DR3 target DNA. EMBO J. 31, 291–300 (2012).
pubmed: 22179700 doi: 10.1038/emboj.2011.445
Bourguet, W. et al. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell 5, 289–298 (2000).
pubmed: 10882070 doi: 10.1016/S1097-2765(00)80424-4
Duda, K., Chi, Y.-I. & Shoelson, S. E. Structural basis for HNF-4α activation by ligand and coactivator binding. J. Biol. Chem. 279, 23311–23316 (2004).
pubmed: 14982928 doi: 10.1074/jbc.M400864200
Gampe, R. T. et al. Asymmetry in the PPARγ/RXRα crystal structure reveals the molecular basis of heterodimerization among nuclear receptors. Mol. Cell 5, 545–555 (2000).
pubmed: 10882139 doi: 10.1016/S1097-2765(00)80448-7
Svensson, S. et al. Crystal structure of the heterodimeric complex of LXRα and RXRβ ligand-binding domains in a fully agonistic conformation. EMBO J. 22, 4625–4633 (2003).
pubmed: 12970175 pmcid: 212723 doi: 10.1093/emboj/cdg456
Yi, P. et al. Structure of a biologically active estrogen receptor–coactivator complex on DNA. Mol. Cell 57, 1047–1058 (2015).
pubmed: 25728767 pmcid: 4369429 doi: 10.1016/j.molcel.2015.01.025
Wasmuth, E. V. et al. Allosteric interactions prime androgen receptor dimerization and activation. Mol. Cell 82, 2021–2031(2022).
pubmed: 35447082 doi: 10.1016/j.molcel.2022.03.035
Yu, X. et al. Structural insights of transcriptionally active, full-length androgen receptor coactivator complexes. Mol. Cell 79, 812–823.e814 (2020).
pubmed: 32668201 pmcid: 7483370 doi: 10.1016/j.molcel.2020.06.031
Hegelund Myrbäck, T. et al. Effects of a selective glucocorticoid receptor modulator (AZD9567) versus prednisolone in healthy volunteers: two phase 1, single-blind, randomised controlled trials. Lancet Rheumatol. 2, e31–e41 (2020).
doi: 10.1016/S2665-9913(19)30103-1
Ripa, L. et al. Discovery of a novel oral glucocorticoid receptor modulator (AZD9567) with improved side effect profile. J. Med. Chem. 61, 1785–1799 (2018).
pubmed: 29424542 doi: 10.1021/acs.jmedchem.7b01690
Liu, X. et al. Disruption of a key ligand-H-bond network drives dissociative properties in vamorolone for Duchenne muscular dystrophy treatment. Proc. Natl Acad. Sci. USA 117, 24285–24293 (2020).
pubmed: 32917814 pmcid: 7533876 doi: 10.1073/pnas.2006890117
Edman, K. et al. Ligand binding mechanism in steroid receptors: from conserved plasticity to differential evolutionary constraints. Structure 23, 2280–2290 (2015).
pubmed: 26602186 doi: 10.1016/j.str.2015.09.012
Weis, D. D. (ed) Hydrogen Exchange Mass Spectrometry of Proteins: Fundamentals, Methods, and Applications (John Wiley & Sons, Ltd, 2016).
Heck, S. et al. A distinct modulating domain in glucocorticoid receptor monomers in the repression of activity of the transcription factor AP-1. EMBO J. 13, 4087–4095 (1994).
pubmed: 8076604 pmcid: 395330 doi: 10.1002/j.1460-2075.1994.tb06726.x
Hurley, D. M. et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J. Clin. Investig. 87, 680–686 (1991).
pubmed: 1704018 pmcid: 296359 doi: 10.1172/JCI115046
Benedek, T. G. History of the development of corticosteroid therapy. Clin. Exp. Rheumatol. 29, S-5-12 (2011).
pubmed: 22018177
Gehring, U. & Hotz, A. Photoaffinity labeling and partial proteolysis of wild-type and variant glucocorticoid receptors. Biochemistry 22, 4013–4018 (1983).
pubmed: 6351915 doi: 10.1021/bi00286a004
Simons, S. S. Jr & Thompson, E. B. Dexamethasone 21-mesylate: an affinity label of glucocorticoid receptors from rat hepatoma tissue culture cells. Proc. Natl Acad. Sci. USA 78, 3541–3545 (1981).
Hollenberg, S. M. et al. Primary structure and expression of a functional human glucocorticoid receptor cDNA. Nature 318, 635–641 (1985).
pubmed: 2867473 pmcid: 6165583 doi: 10.1038/318635a0
Miesfeld, R. et al. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. Cell 46, 389–399 (1986).
pubmed: 3755378 doi: 10.1016/0092-8674(86)90659-8
Hudson, W. H. et al. Distal substitutions drive divergent DNA specificity among paralogous transcription factors through subdivision of conformational space. Proc. Natl Acad. Sci. USA 113, 326–331 (2016).
pubmed: 26715749 doi: 10.1073/pnas.1518960113
Galliher-Beckley, A. J., Williams, J. G., Collins, J. B. & Cidlowski, J. A. Glycogen synthase kinase 3β-mediated serine phosphorylation of the human glucocorticoid receptor redirects gene expression profiles. Mol. Cell. Biol. 28, 7309–7322 (2008).
pubmed: 18838540 pmcid: 2593428 doi: 10.1128/MCB.00808-08
Carlsson, P., Koehler, K. F. & Nilsson, L. Glucocorticoid receptor point mutation V571M facilitates coactivator and ligand binding by structural rearrangement and stabilization. Mol. Endocrinol. 19, 1960–1977 (2005).
pubmed: 15774500 doi: 10.1210/me.2004-0203
Kauppi, B. et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J. Biol. Chem. 278, 22748–22754 (2003).
pubmed: 12686538 doi: 10.1074/jbc.M212711200
Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D 67, 293–302 (2011).
McCoy, A. J. et al. Phaser crystallographic software. J. Appl. Crystallogr. 40, 658–674 (2007).
pubmed: 19461840 pmcid: 2483472 doi: 10.1107/S0021889807021206
Bricogne, G. et al. BUSTER (Global Phasing, 2017).
Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010).
Krissinel, E. & Henrick, K. Inference of macromolecular assemblies from crystalline state. J. Mol. Biol. 372, 774–797 (2007).
pubmed: 17681537 doi: 10.1016/j.jmb.2007.05.022
Kabsch, W. A solution for the best rotation to relate two sets of vectors. Acta Crystallogr. A 32, 922–923 (1976).
doi: 10.1107/S0567739476001873
Altschul, S. F. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25, 3389–3402 (1997).
pubmed: 9254694 pmcid: 146917 doi: 10.1093/nar/25.17.3389
Edgar, R. C. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32, 1792–1797 (2004).
pubmed: 15034147 pmcid: 390337 doi: 10.1093/nar/gkh340
Masson, G. R. et al. Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments. Nat. Methods 16, 595–602 (2019).
pubmed: 31249422 pmcid: 6614034 doi: 10.1038/s41592-019-0459-y
Gluzman, Y. SV40-transformed simian cells support the replication of early SV40 mutants. Cell 23, 175–182 (1981).
pubmed: 6260373 doi: 10.1016/0092-8674(81)90282-8

Auteurs

Sandra Postel (S)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Lisa Wissler (L)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Carina A Johansson (CA)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Anders Gunnarsson (A)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Euan Gordon (E)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Barry Collins (B)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Marie Castaldo (M)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Christian Köhler (C)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

David Öling (D)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Patrik Johansson (P)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Linda Fröderberg Roth (L)

Discovery Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden.

Brice Beinsteiner (B)

Centre for Integrative Biology (CBI), Department of Integrated Structural Biology, Institute of Genetics and of Molecular and Cellular Biology (IGBMC), Illkirch, France.
Université de Strasbourg, Illkirch, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), Illkirch, France.
Centre National de la Recherche Scientifique (CNRS) UMR 7104, Illkirch, France.

Ian Dainty (I)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Stephen Delaney (S)

Bioscience COPD/IPF, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.

Bruno P Klaholz (BP)

Centre for Integrative Biology (CBI), Department of Integrated Structural Biology, Institute of Genetics and of Molecular and Cellular Biology (IGBMC), Illkirch, France.
Université de Strasbourg, Illkirch, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), Illkirch, France.
Centre National de la Recherche Scientifique (CNRS) UMR 7104, Illkirch, France.

Isabelle M L Billas (IML)

Centre for Integrative Biology (CBI), Department of Integrated Structural Biology, Institute of Genetics and of Molecular and Cellular Biology (IGBMC), Illkirch, France.
Université de Strasbourg, Illkirch, France.
Institut National de la Santé et de la Recherche Médicale (INSERM), Illkirch, France.
Centre National de la Recherche Scientifique (CNRS) UMR 7104, Illkirch, France.

Karl Edman (K)

Mechanistic & Structural Biology, Discovery Sciences, R&D, AstraZeneca, Gothenburg, Sweden. karl.edman@astrazeneca.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH